New HIV drug IAP086 enters first human safety trial
NCT ID NCT07596888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether a single dose of an experimental drug called IAP086 is safe in 30 adults with HIV whose virus is already well-controlled by standard antiretroviral therapy. Participants receive one intravenous infusion and are monitored closely for 28 days. The main goal is to check for side effects, not to measure how well the drug works against HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IAP086 (an experimental drug given as a single intravenous infusion)
What this could lead to
If safe, this could pave the way for larger studies exploring whether IAP086 helps control HIV without daily pills.
What could go wrong
This is a very early, small Phase 1 safety trial in 30 people. It is not designed to test effectiveness, and the drug may cause side effects or fail in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of North Carolina
RECRUITINGChapel Hill, North Carolina, 27514, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••